AGP
Artia Global Partners Portfolio holdings
AUM
$389M
This Quarter Return
+4.92%
1 Year Return
+34.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$390M
AUM Growth
+$390M
(-4.4%)
Cap. Flow
-$27.1M
Cap. Flow
% of AUM
-6.96%
Top 10 Holdings %
Top 10 Hldgs %
82.6%
Holding
55
New
7
Increased
8
Reduced
8
Closed
12
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$8.51M |
| 2 |
Merck
MRK
|
$7.84M |
| 3 |
Ionis Pharmaceuticals
IONS
|
$2.98M |
| 4 |
Celldex Therapeutics
CLDX
|
$2.79M |
| 5 |
Soleno Therapeutics
SLNO
|
$2.18M |
Top Sells
| 1 |
AbbVie
ABBV
|
$16.5M |
| 2 |
argenx
ARGX
|
$8.21M |
| 3 |
Cytokinetics
CYTK
|
$6.28M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$4.69M |
| 5 |
Insmed
INSM
|
$4.34M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Novo Nordisk
NVO
$251B
| $98.7M | 19.09% |
691,743
| – | – |
|
2
Eli Lilly
LLY
$657B
| $83.8M | 16.2% |
92,593
| – | – |
|
|
3
Merck
MRK
$210B
| $54.8M | 10.59% |
442,504
+63,304
| +17% | +$7.84M |
|
4
Viking Therapeutics
VKTX
$3.04B
| $24M | 4.64% |
452,979
+19,399
| +4% | +$1.03M |
|
5
AstraZeneca
AZN
$248B
| $14.9M | 2.88% |
190,752
| – | – |
|
|
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $14.8M | 2.87% |
216,519
+6,423
| +3% | +$440K |
|
|
7
Vertex Pharmaceuticals
VRTX
$100B
| $8.86M | 1.71% |
18,900
-10,000
| -35% | -$4.69M |
|
|
8
Alnylam Pharmaceuticals
ALNY
$58.5B
| $8.51M | 1.64% |
+35,000
| New | +$8.51M |
|
9
Axsome Therapeutics
AXSM
$6.05B
| $7.07M | 1.37% |
87,848
| – | – |
|
|
10
argenx
ARGX
$43.6B
| $6.51M | 1.26% |
15,138
-19,100
| -56% | -$8.21M |
|
11
Neurocrine Biosciences
NBIX
$13.8B
| $6.2M | 1.2% |
45,000
| – | – |
|
12
Vaxcyte
PCVX
$4B
| $5.76M | 1.11% |
76,255
| – | – |
|
13
Protagonist Therapeutics
PTGX
$3.67B
| $4.31M | 0.83% |
124,440
| – | – |
|
14
Dyne Therapeutics
DYN
$1.92B
| $4.22M | 0.82% |
119,488
| – | – |
|
|
15
Soleno Therapeutics
SLNO
$3.6B
| $3.85M | 0.74% |
94,424
+53,500
| +131% | +$2.18M |
|
16
Crinetics Pharmaceuticals
CRNX
$2.92B
| $3.84M | 0.74% |
85,765
| – | – |
|
|
17
Insmed
INSM
$28.8B
| $3.58M | 0.69% |
53,436
-64,800
| -55% | -$4.34M |
|
18
Ocular Therapeutix
OCUL
$2.12B
| $3.42M | 0.66% |
500,000
-224,685
| -31% | -$1.54M |
|
|
19
Ionis Pharmaceuticals
IONS
$6.79B
| $2.98M | 0.58% |
+62,479
| New | +$2.98M |
|
20
Merus
MRUS
$4.98B
| $2.97M | 0.57% |
50,171
| – | – |
|
|
21
Celldex Therapeutics
CLDX
$1.47B
| $2.79M | 0.54% |
+75,300
| New | +$2.79M |
|
22
Apogee Therapeutics
APGE
$2.17B
| $2.3M | 0.44% |
58,400
-3,190
| -5% | -$126K |
|
|
SWTX
23
DELISTED
SpringWorks Therapeutics
SWTX
| $2.03M | 0.39% |
53,930
| – | – |
|
24
IDEAYA Biosciences
IDYA
$2.15B
| $1.91M | 0.37% |
54,392
+1,900
| +4% | +$66.7K |
|
|
VRNA
25
Verona Pharma
VRNA
$9.16B
| $1.89M | 0.37% |
130,790
| – | – |
|